STAAR Surgical Company

    Jurisdiction
    United States
    LEI
    5299006LRHI7OJ8BY308
    ISIN
    US8523123052 (STAA)
    Sectors
    1. Healthcare
    2. Medical - Instruments & Supplies

    Scores

    InsiderPie Expert Score
    51 / 100
    Even with peer group:
    51 / 100
    Fair value (Benjamin Graham formula)
    €10.92 106.4% overvalued
    Financial strength (Piotroski F-Value)
    1 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. Read full profile

    Fundamentals

    Net revenue
    €191.44M
    Gross margin
    71.7%
    EBIT
    -€93.48M
    EBIT margin
    -48.8%
    Net income
    -€81.26M
    Net margin
    -42.4%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €273.64M +42.9% -€7.78M -90.4%
    €294.15M +7.5% €9.92M -227.5%
    €327.39M +11.3% €6.40M -35.5%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 65K $1.15M -73K Sell

    Earnings Calls

    Latest earnings call: May 7, 2025 (Q1 2025)

    Add to watchlist

    Notifications